surovatamig surovatamig PHASE3
Drug Profile
ModalityBispecific
RouteIV
Therapy AreaOncology
Peak Sales Est$1500M
Formulations[]
Companies
AZN (ORIGINATOR)100%
Mechanism: DLL3 T-cell engager
Expert: Bispecific T-cell engager targeting DLL3 on tumor cells and CD3 on T-cells, inducing T-cell mediated cytotoxicity of SCLC.
Everyday: Brings immune T-cells directly to cancer cells expressing DLL3 protein, common in small cell lung cancer.
Targets: ["DLL3"]
Programs (1)
IndicationStageKey StudyRegional Status
Adv solidPHASE1[]
Notes
CD19/CD3 T-cell engager for lymphomas.
Data from Supabase · Updated 2026-03-24